

BY HAND DELIVERY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jove *et al.*

Confirmation No.: 1344

Serial No.: 09/492,764

Art Unit: 1642

Filed: January 27, 2000

Examiner: Rawlings, S.

For: INHIBITION OF STAT3 SIGNAL  
TRANSDUCTION FOR HUMAN CANCER  
THERAPY

Attorney Docket No: 10873-008-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97 & §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references CJ-CY listed on the attached revised form PTO 1449. References CJ-CY were cited in a Search Report and Written Opinion for a foreign application that is a counterpart to the above-identified application. A copy of each of references CJ-CY is provided herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of an "Information Disclosure Citation in an Application".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


03 SEP 10 11:40:09  
RECEIVED  
COMM-FEDERAL

A  
26  
KJ  
9/12/03

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date September 10, 2003

  
Adriane M. Antler 32,605  
(Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.  
10873-008-999

APPLICATION NO  
09/492,764

APPLICANT  
Jove et al.

FILING DATE  
January 27, 2000

GROUP  
1642

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CJ	5,935,993	8/10/99	Tang et al.			
	CK	5,972,598	10/26/99	Chaudhary et al.			
	CL	6,426,366	7/30/02	Novogrodsky et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

	CM	Bright et al. IL-12 induced JAK-STAT pathways in T lymphocytes: Regulation by tyrphostin. J. of Allergy and Clinical Immunology, 1997, 99(1 part 2):S287. Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society; San Francisco, CA, USA; February 21-26, 1997
	CN	Burger et al. IL-6 induced proliferation of a myeloma cell line is accompanied by activation of the JAK/STAT pathway and inhibited by tyrphostin AG490. Annals of Hematology, 1998, 77(suppl. 2):S2
	CO	Han et al. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. Oncol Res. 1997, 9(11-12):581-587
	CP	Han et al. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 1996, 56(17):3859-3861
	CQ	Heller et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. DATABASE BIOSIS (online), Biosciences information service, Philadelphia, PA, US; July 1, 1998, Database accession No. PREV199800321817. Abstract & cancer, 83(1):148-157
	CR	Lei et al. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res. 1999, 19(1A):221-228
	CS	Liang et al. Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17. Clin Cancer Res. 1998, 4(3):773-781
	CT	Nielsen et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(13):6764-6769
	CU	Palumbo et al. The tryphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res. 1997, 57(12):2434-2439
	CV	Penar et al. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery. 1997, 40(1):141-151

	CW	Tsai et al. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 1996, 56(5):1068-1074
	CX	Zushi et al. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer. 1998, 78(3):326-330
	CY	Zushi et al. Role of heparin-binding EGF-related peptides in proliferation and apoptosis of activated ras-stimulated intestinal epithelial cells. Int. J. Cancer 1997, 73(6):917-923

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.